HVSEN BIOTECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.3 CNY | -1.79% |
|
+13.31% | -1.11% |
| Apr. 24 | Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 03 | Hvsen Biotechnology Co., Ltd. announced a financing transaction | CI |
| Sales 2024 * | 1.92B 265M | Sales 2025 * | 2.8B 388M | Capitalization | 2.34B 323M |
|---|---|---|---|---|---|
| Net income 2024 * | 103M 14.23M | Net income 2025 * | 276M 38.13M | EV / Sales 2024 * | 1.22 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.83 x |
| P/E ratio 2024 * |
23.1
x | P/E ratio 2025 * |
8.61
x | Employees | 957 |
| Yield 2024 * |
0.84% | Yield 2025 * |
3.5% | Free-Float | 40.11% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.79% | ||
| 1 week | +13.31% | ||
| Current month | +5.61% | ||
| 1 month | +19.67% | ||
| 3 months | +18.18% | ||
| 6 months | +0.56% | ||
| Current year | -1.11% |
1 week
12.16
14.87
1 month
11.6516.49
Current year
7.6116.49
1 year
7.6118.50
3 years
7.6152.40
5 years
7.6158.66
10 years
7.6158.66
| Managers | Title | Age | Since |
|---|---|---|---|
Kai Jie Yang
CEO | Chief Executive Officer | 54 | 14-04-30 |
Jian Zhou
CHM | Chairman | 50 | 09-07-31 |
Jie Liu
BRD | Director/Board Member | 60 | 12-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Huo Bao Xie
BRD | Director/Board Member | 56 | 16-12-09 |
Wei Yuan Zhang
FOU | Founder | 55 | 02-01-24 |
Zhen Ling Zeng
BRD | Director/Board Member | 61 | 16-12-09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 14.3 | -1.79% | 2 772 890 |
| 24-04-24 | 14.56 | +2.18% | 1,945,545 |
| 24-04-23 | 14.25 | +0.21% | 3,206,869 |
| 24-04-22 | 14.22 | +5.49% | 4,420,175 |
| 24-04-19 | 13.48 | +9.15% | 4,455,175 |
End-of-day quote Shenzhen S.E., April 24, 2024
More quotes
Wuhan Hvsen Biotechnology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of veterinary drugs, feed and additives. The Companyâs main products include veterinary active pharmaceutical ingredients, veterinary chemical preparations, veterinary traditional Chinese medicine preparations, feed and additives and environmental improvers, such as tyvanicin tartrate, florfenicol powder, banqing granules and piglet composites pre-mixed feed, etc. The Company mainly conducts its businesses in the China market.
Sector
Pharmaceuticals
Calendar
2024-04-24
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
14.3
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -1.11% | 329M | |
| -23.08% | 68.94B | |
| +18.88% | 3.43B | |
| -3.62% | 3.22B | |
| -2.87% | 1.46B | |
| -15.41% | 1.38B | |
| -4.30% | 1.26B | |
| -27.74% | 1.21B | |
| -13.54% | 1.14B | |
| -2.99% | 1.02B |
- Stock Market
- Equities
- 300871 Stock
